Cardiac Safety of Indacaterol

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Healthy, non-smoking

• Body mass index (BMI) 18.5-32 kg/m2

• Body weight at least 50 kg

Exclusion Criteria:

• Recent/concurrent use of concomitant medications (except acetaminophen)

• Recent participation in other clinical trials

• Recent donation or loss of blood

• History/presence of a range of medical conditions, including electrocardiographic (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function

Other protocol-defined inclusion/exclusion criteria may apply